NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
8/100
Mechanism of Action
MOCS1 gene leading to deficient MOCS1A/B dependent synthesis of the intermediate substrate, cPMP. Substrate replacement therapy with NULIBRY provides an exogenous source of cPMP, which is converted to molybdopterin. Molybdopterin is then converted to molybdenum cofactor, which is needed for the…
Loss of Exclusivity
LOE Date
Apr 9, 2029
37 months away
Patent Expiry
Apr 9, 2029
Exclusivity Expiry
Feb 26, 2028
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7504095 | Apr 9, 2029 | Product | U-3092 |